Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients
4
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The current study was conducted in order to evaluate the clinical outcome of radical radiotherapy (RT) with or without chemotherapy for elderly patients with stage III non-small cell lung cancer (NSCLC). Materials and Methods Between 1990 and 2010, 125 patients, aged 70 years or more, received radical RT with or without chemotherapy for treatment of stage III NSCLC. We reviewed the patients’prognostic factors, including comorbidities. Comorbidity status was evaluated using a simplified comorbidity score (SCS). Of the patients reviewed, 82 received radical RT alone,whereas the other 43 patients underwent chemoradiotherapy (CRT). A platinum-based chemotherapy regimen was most commonly used (42/43). Results The two-year overall-survival (OS) and progression-free survival (PFS) rates were 32.2%and 21.8%, respectively. SCS was the independent prognostic factor for OS. In the frail elderly subgroup with a SCS of ≥10, CRT demonstrated a significant difference in PFS, but not in OS. In contrast, OS and PFS following CRT were significantly superior to RT in the fit elderly subgroup with a SCS of <10. The incidence of severe pulmonary toxicities in the frail elderly subgroup was significantly higher than that in the fit elderly subgroup. Conclusion Multiple comorbidities evaluated according to the SCS are related to poor OS in elderly patients with stage III NSCLC. CRT improved clinical outcome when compared to RT in the fit elderly subgroup, however, the gain from this treatment was negated in the frail elderly subgroup with multiple comorbidities. Therefore, evaluation of comorbidity is necessary in order to determine whether chemotherapy should be combined with RT in elderly patients with stage III NSCLC.
Abstract
Purpose The current study was conducted in order to evaluate the clinical outcome of radical radiotherapy (RT) with or without chemotherapy for elderly patients with stage III non-small cell lung cancer (NSCLC). Materials and Methods Between 1990 and 2010, 125 patients, aged 70 years or more, received radical RT with or without chemotherapy for treatment of stage III NSCLC. We reviewed the patients’prognostic factors, including comorbidities. Comorbidity status was evaluated using a simplified comorbidity score (SCS). Of the patients reviewed, 82 received radical RT alone,whereas the other 43 patients underwent chemoradiotherapy (CRT). A platinum-based chemotherapy regimen was most commonly used (42/43). Results The two-year overall-survival (OS) and progression-free survival (PFS) rates were 32.2%and 21.8%, respectively. SCS was the independent prognostic factor for OS. In the frail elderly subgroup with a SCS of ≥10, CRT demonstrated a significant difference in PFS, but not in OS. In contrast, OS and PFS following CRT were significantly superior to RT in the fit elderly subgroup with a SCS of <10. The incidence of severe pulmonary toxicities in the frail elderly subgroup was significantly higher than that in the fit elderly subgroup. Conclusion Multiple comorbidities evaluated according to the SCS are related to poor OS in elderly patients with stage III NSCLC. CRT improved clinical outcome when compared to RT in the fit elderly subgroup, however, the gain from this treatment was negated in the frail elderly subgroup with multiple comorbidities. Therefore, evaluation of comorbidity is necessary in order to determine whether chemotherapy should be combined with RT in elderly patients with stage III NSCLC.
참고문헌 (23)
- Langer C, "Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC(LA-NSCLC)", Lung Cancer, 29, pp.104~ (2000)
- Pfister DG, "American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline : update 2003", J Clin Oncol, 22, pp.330~353 (2004)
- Auperin A, "Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer(NSCLC) : a meta-analysis of individual data from 1764 patients", Ann Oncol, 17, pp.473~483 (2006)
- 조병철, "Treatment of the Elderly When Cure is the Goal The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer", JOURNAL OF THORACIC ONCOLOGY, 6(3), pp.537~544, LIPPINCOTT WILLIAMS & WILKINS
- Piccirillo JF, "Prognostic importance of comorbidity in a hospital-based cancer registry", JAMA, 291, pp.2441~2447 (2004)
- Fentiman IS, "Cancer in the elderly: why so badly treated?", Lancet, 335, pp.1020~1022 (1990)
- Schild SE, "The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly", J Clin Oncol, 21, pp.3201~3206 (2003)
- Atagi S, "Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with nonsmall-cell lung cancer : a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group(JCOG0301)", Lancet Oncol, 13, pp.671~678 (2012)
- Werner-Wasik M, "Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group(RTOG)patients with locally-advanced non-small-cell lung cancer(LA-NSCLC) : identification of five groups with different survival", Int J Radiat Oncol Biol Phys, 48, pp.1475~1482 (2000)
- Jacot W, "Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients", Ann Oncol, 19, pp.1458~1464 (2008)
- Colinet B, "A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index", Br J Cancer, 93, pp.1098~1105 (2005)
- Semrau S, "Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy", Respir Med, 102, pp.210~218 (2008)
- Martine Extermann, "Geriatric Oncology: An Overview of Progresses and Challenges", Cancer Research and Treatment, 42(2), pp.61~68 (2010), 대한암학회
- Gronberg BH, "Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy", Eur J Cancer, 46, pp.2225~2234 (2010)
- Cox JD, "Toxicity criteria of the Radiation Therapy Oncology Group(RTOG)and the European Organization for Research and Treatment of Cancer(EORTC)", Int J Radiat Oncol Biol Phys, 31, pp.1341~1346 (1995)
- Langer CJ, "Elderly patients(pts)with locally advanced non-small cell lung cancer(LA-NSCLC)benefit from combined modality therapy : secondary analysis of Radiation Therapy Oncology Group(RTOG)94-10", Proc Am Soc Clin Oncol, 21, pp.1193~ (2002)
- De Ruysscher D, "Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients : a prospective, population-based study", Ann Oncol, 20, pp.98~102 (2009)
- Davidoff AJ, "Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer", J Thorac Oncol, 6, pp.934~941 (2011)
- Rao AV, "Geriatric assessment and comorbidity", Semin Oncol, 31, pp.149~59 (2004)
- Girones R, "Prognostic impact of comorbidity in elderly lung cancer patients : use and comparison of two scores", Lung Cancer, 72, pp.108~113 (2011)
- Liu JJ, "Comprehensive geriatric assessment and its clinical impact in oncology", Clin Geriatr Med, 28, pp.19~31 (2012)
- Dancey J, "The National Cancer Institute of Canada Clinical Trials Group", Qual Life Res, 6, pp.151~158 (1997)
- Schneeweiss S, "Use of comorbidity scores for control of confounding in studies using administrative databases", Int J Epidemiol, 29, pp.891~898 (2000)